Literature DB >> 6727279

Non-additive positive inotropic effects of amrinone and ouabain on cat papillary muscles.

L Brown, E Erdmann.   

Abstract

Amrinone has been shown to produce haemodynamic benefits in digitalis-treated patients. Since amrinone is a positive inotropic agent on isolated heart muscle, these benefits may mean that amrinone increases the maximal ouabain-induced increase in force of contraction, without causing toxicity. We have therefore measured, in cat right ventricular papillary muscles, the inotropic effects of ouabain, amrinone alone and amrinone with a maximally effective, non-toxic ouabain concentration (2 X 10(-7) M). Ouabain is much more potent than amrinone (EC50-values: ouabain, 8 X 10(-8) M, amrinone, 1-2.8 X 10(-3) M). The highest amrinone concentration used (6 X 10(-3) M) produced a significantly lower increase in force of contraction than ouabain (2 X 10(-7) M) in the same muscles. After ouabain (2 X 10(-7) M) produced a stable effect, no further increase in force of contraction was observed with any amrinone concentration. Sustained arrhythmias were observed in five of six muscles at 3 X 10(-3) M amrinone with ouabain (2 X 10(-7) M), but in only one of these muscles with amrinone 3 X 10(-3) M alone. Since the positive inotropic effects of amrinone are not additive with those from a maximally effective ouabain concentration, the haemodynamic benefits seen in patients are probably due to non-cardiac effects of amrinone such as vasodilatation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6727279     DOI: 10.1007/BF01742294

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  22 in total

1.  Cardiotonic activity of amrinone--Win 40680 [5-amino-3,4'-bipyridine-6(1H)-one].

Authors:  A A Alousi; A E Farah; G Y Lesher; C J Opalka
Journal:  Circ Res       Date:  1979-11       Impact factor: 17.367

Review 2.  Beta 2 adrenoceptor agonists. Pharmacology, metabolic effects and arrhythmias.

Authors:  R Canepa-Anson; J R Dawson; W S Frankl; P Kuan; G C Sutton; S Reuben; P A Poole-Wilson
Journal:  Eur Heart J       Date:  1982-12       Impact factor: 29.983

3.  Comparison of the affinity of human, beef and cat heart (Na+ + K+)-ATPase for different digitalis derivatives.

Authors:  L Brown; E Erdmann
Journal:  Arzneimittelforschung       Date:  1984

4.  Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure.

Authors:  T H LeJemtel; E Keung; H S Ribner; R Davis; J Wexler; J D Blaufox; E H Sonnenblick
Journal:  Am J Cardiol       Date:  1980-01       Impact factor: 2.778

5.  Cardiovascular response to increasing theophylline concentrations.

Authors:  R I Ogilvie; P G Fernandez; F Winsberg
Journal:  Eur J Clin Pharmacol       Date:  1977-12-28       Impact factor: 2.953

6.  Oral amrinone in refractory congestive heart failure.

Authors:  J Wynne; R F Malacoff; J R Benotti; G D Curfman; W Grossman; B L Holman; T W Smith; E Braunwald
Journal:  Am J Cardiol       Date:  1980-06       Impact factor: 2.778

7.  Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle.

Authors:  M Endoh; S Yamashita; N Taira
Journal:  J Pharmacol Exp Ther       Date:  1982-06       Impact factor: 4.030

8.  Cardiac effects of amrinone on rabbit papillary muscle and guinea pig Langendorff heart preparations.

Authors:  G Onuaguluchi; R D Tanz
Journal:  J Cardiovasc Pharmacol       Date:  1981 Nov-Dec       Impact factor: 3.105

9.  Amrinone relaxes potassium-induced contracture of failing right ventricular muscle of cats.

Authors:  M S Gaide; W S Fitterman; J R Wiggins; R J Myerburg; J S Cameron; A L Bassett
Journal:  J Cardiovasc Pharmacol       Date:  1983 Mar-Apr       Impact factor: 3.105

10.  Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate.

Authors:  J Bayliss; M Norell; R Canepa-Anson; S R Reuben; P A Poole-Wilson; G C Sutton
Journal:  Br Heart J       Date:  1983-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.